SecBot SecBot

NVO drug pipeline

NOVO NORDISK A S · 21 rated drugs
$41.60
−0.1% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±1.8%
1-day, median of 14 events
IV rank
No data
No current options data
Rated drugs
21
1 bearish · 1 mixed · 19 neutral
Phase 3 trials
24
7 with results posted

Upcoming catalysts

3 dated
  1. Dec 14, 2026
    NNC0662-0419
    Phase 2 primary completion
  2. Jan 25, 2027
    Awiqli
    Phase 3 primary completion
  3. Jan 29, 2027
    Ziltivekimab
    Phase 3 primary completion

Drugs

soonest catalyst first
◆ mixed
Impact
PhasePhase 3 (multiple trials completed; results pending)
Time to marketPhase 3 trials are complete but results have not yet been posted and no regulatory submission/approval is recorded in local FDA data — realistically 1-2+ years from now if readouts support filing; unknown otherwise.

CagriSema cagrilintide + semaglutide (fixed-dose combination) Updated Aug 1

What to watch

Watch for the pending Phase 3 topline readouts (obesity and T2D-vs-tirzepatide), they are the key binary for the CagriSema thesis in the next quarter or two, since no efficacy numbers are yet posted to ClinicalTrials.gov in the local data and no FDA approval action exists. Note the bearish analyst backdrop (consensus is Hold-heavy and mean target ~$47.79 vs ~$47-52 price, with six 2025-26 downgrades) and that a sister-pipeline failure (ziltivekimab ZEUS, HR 0.99) just hit NVO on 2026-07-31, so positive readouts may be needed just to stabilize sentiment.

Bull case
  • Phase 3 program is essentially complete across obesity and T2D, including head-to-head trials vs Lilly's tirzepatide (NCT06131437 obesity; NCT06534411 and NCT06221969 in T2D) and a 2,734-patient trial vs semaglutide/cagrilintide/placebo (NCT06065540), per local ClinicalTrials.gov-derived records.
  • Local event data flags the completed obesity and T2D Phase 3 trials as 'results pending, data readout imminent', meaning the market's next hard catalyst is close; a strong readout would re-rate the obesity franchise at a ~$228B-market-cap company (market cap from the 2026-07-31 6-K analysis).
  • Low short interest: FINRA semi-monthly positions show 31.09M shares short at the 2026-07-15 settlement, ~0.70% of estimated shares outstanding (days-to-cover 3.34), not a crowded short setup.
Bear case
  • No approval and no regulatory catalyst in local FDA data, zero FDA actions/catalysts matched for CagriSema, so the only near-term events are trial readouts, which are binary and could disappoint.
  • Every key Phase 3 trial in the local records shows results NOT yet posted (hasResults=false); the actual weight-loss/A1c numbers are unconfirmed, so the bull case is currently expectation, not evidence.
  • Head-to-head trials vs tirzepatide mean CagriSema must prove superiority or at least parity-plus against Lilly's already-approved Zepbound/Mounjaro, a high bar in the most competitive category in pharma.
● neutral
Impact
PhasePhase 3
Time to marketIf Phase 3 trials succeed, a regulatory filing could occur around 2028-2029 for the non-cirrhotic MASH indication (SYNCHRONY Histology data expected H2 2027). The compensated cirrhosis indication (SYNCHRONY Outcomes) has a primary completion date around 2030.

efruxifermin Updated Nov 6

What to watch

The next catalyst is the SYNCHRONY Real-World safety readout expected in Q4 2026 (imminent), plus ongoing data presentations at AASLD 2026 (Nov 5-9). Positive safety data would support the Phase 3 program's viability; negative safety signals could delay or derail the program. The pivotal efficacy readout (SYNCHRONY Histology, F2-F3) is not expected until H2 2027, so near-term binary risk for NVO shareholders is limited given the drug is one of many pipeline assets at a mega-cap company.

Bull case
  • Efruxifermin is the first and only drug to demonstrate reversal of compensated cirrhosis due to MASH in clinical trials, with up to 39% of patients achieving fibrosis improvement at 50 mg in Phase 2b SYMMETRY (HCPLive, 2025).
  • Phase 2b HARMONY 96-week data showed robust and durable fibrosis improvement, with ~41% of patients on the higher dose achieving at least one-stage fibrosis improvement without worsening of MASH (The Lancet, 2025).
  • FDA granted Breakthrough Therapy Designation, which can expedite development and review (Akero press release, Dec 2025).
Bear case
  • Phase 2b SYMMETRY trial in compensated cirrhosis (F4) missed its primary endpoint at week 36, raising questions about efficacy in advanced disease (NEJM, May 2025).
  • Treatment discontinuation due to adverse events was higher with efruxifermin (16-18%) vs placebo (2%) in Phase 2 trials, and ~90% of patients developed anti-drug antibodies (The Lancet, 2025).
  • Resmetirom (Madrigal) is already FDA-approved for MASH with F2-F3 fibrosis, and tirzepatide (Eli Lilly) and other FGF21 analogs (pegozafermin) are in late-stage development, creating a competitive landscape.
● neutral
Impact
PhasePhase 3 (completed pivotal trial)
Time to marketRegulatory submission to the FDA is expected imminently (H2 2026). If filed, a standard FDA review would take approximately 6-12 months, suggesting a potential approval decision in the second half of 2027 at the earliest.

etavopivat Updated Nov 6

What to watch

Watch for Novo Nordisk's regulatory submission of etavopivat to the FDA, expected in the second half of 2026 (imminent). If filed, a PDUFA date would be set roughly 6-12 months later. The key competitive dynamic is Agios' mitapivat, which has a PDUFA date of February 1, 2027 for the same sickle cell indication. Etavopivat's once-daily dosing could be a differentiator versus mitapivat's twice-daily regimen.

Bull case
  • Etavopivat met both co-primary endpoints in the pivotal Phase 3 HIBISCUS trial: a 27% reduction in vaso-occlusive crisis events and a 48.7% hemoglobin response rate at week 24 (vs 7.2% placebo), establishing proof of concept as a potential first-in-class oral PKR activator for sickle cell disease.
  • Once-daily oral dosing is a convenience advantage over competitor mitapivat (Agios), which requires twice-daily dosing, potentially improving patient adherence.
  • Novo Nordisk acquired etavopivat via the $1.1 billion Forma Therapeutics acquisition in 2022, and the positive Phase 3 data validates that acquisition thesis, with regulatory filings being prepared for H2 2026.
Bear case
  • Etavopivat has not yet been submitted for FDA review as of November 2026, while competitor Agios' mitapivat already has a PDUFA date of February 1, 2027 for sickle cell disease, meaning mitapivat could reach the market first.
  • The 27% reduction in vaso-occlusive crises, while statistically significant, is modest and may face reimbursement or prescriber adoption challenges versus existing and emerging therapies.
  • Etavopivat is a very small part of Novo Nordisk's overall business (dominated by GLP-1 diabetes/obesity franchise), so even a successful approval would have limited impact on NVO's share price.
● neutral
Impact
PhasePhase 3 (FRONTIER program)
Time to marketEU launch in initial countries expected Q4 2026 (pending European Commission decision); US launch targeted for H1 2027 (contingent on FDA approval after manufacturing remediation).

Frehemgo denecimig Updated Nov 5

What to watch

The next hard catalyst is the European Commission decision on Frehemgo's EU marketing authorization, expected imminently (CHMP positive opinion was September 17, 2026, and EC typically rules within ~2 months). An approval would enable Q4 2026 launches in initial European countries. In the US, the FDA review remains delayed with no new PDUFA date, though Novo targets H1 2027 launch. For NVO, a $2-3B peak-sales hemophilia A drug is a modest addition to a GLP-1-dominated franchise, not a company-defining binary.

Bull case
  • Phase 3 FRONTIER2 results published in NEJM showed denecimig dramatically reduced annualized bleeding rates in hemophilia A patients with or without inhibitors, demonstrating superiority over prior factor prophylaxis.
  • Frehemgo is the first FVIIIa mimetic offering once-monthly, once-every-two-weeks, and once-weekly dosing in a single pre-filled pen, a convenience advantage over Hemlibra's weekly or biweekly dosing.
  • CHMP recommended EU approval in September 2026, and the European Commission decision is expected imminently, with first EU country launches planned for Q4 2026.
Bear case
  • Frehemgo faces entrenched competition from Roche's Hemlibra (emicizumab), which dominates the hemophilia A prophylaxis market with strong prescriber satisfaction and a head start of several years.
  • The FDA review is delayed indefinitely due to manufacturing facility remediation issues, with no new PDUFA date set, pushing potential US launch to at least H1 2027 and creating regulatory overhang.
  • Novo Nordisk received an FDA warning letter in March 2026 for its Plainsboro, New Jersey facility over adverse event reporting failures, signaling broader manufacturing quality concerns.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed (injectable since 2021; oral pill since January 2026).

Wegovy semaglutide Updated Oct 27

What to watch

The next major catalyst for NVO shares tied to Wegovy is the Q3 2026 earnings report expected around November 4, 2026, where investors will scrutinize oral Wegovy pill sales trajectory and whether injectable Wegovy market share is stabilizing against Zepbound competition. Longer-term, watch for China approval of oral Wegovy and the Viatris patent challenge.

Bull case
  • Wegovy is a first-in-class GLP-1 franchise with multiple formulations: injectable (2.4 mg, 7.2 mg) and the first FDA-approved oral GLP-1 for obesity (December 2025, launched January 2026), giving Novo a unique oral-first option against Lilly's injectable Zepbound.
  • CV outcomes data from the SELECT trial (20% MACE risk reduction) provides a label advantage and a differentiation story, Sep 2026 real-world evidence suggested higher semaglutide doses show cardiovascular edge over tirzepatide in MACE reduction (source: MSN, Sept 29, 2026).
  • Oral Wegovy pill demonstrated rapid early uptake: >100,000 new prescriptions within the first two months of launch, and within 10 weeks oral semaglutide initiation rates briefly exceeded injectable (source: Newswise, Oct 6, 2026; AJMC, Oct 23, 2026).
Bear case
  • Intense competition from Eli Lilly's Zepbound (tirzepatide), which data suggests produces greater weight loss, a September 2026 indirect comparison showed Zepbound 15 mg had >3x the odds of achieving ≥20% weight reduction vs Wegovy HD 7.2 mg (source: MarketScreener, Sept 29, 2026).
  • Patent cliff looming: Viatris filed a lawsuit in September 2026 seeking a declaratory judgment that its generic Wegovy would not infringe Novo Nordisk's patents (source: StreetInsider, Sept 25, 2026).
  • Stock down ~38% over 3 years and ~10% YTD; post-Capital Markets Day in September 2026, shares fell 7% as the company's post-Wegovy growth plan failed to ease competition fears (source: CNBC, Sept 21, 2026).
● neutral
Impact
PhasePhase 3
Time to marketIf Phase 3 trials succeed, a regulatory filing would likely come no earlier than 2028-2029, with potential approval in the 2029-2030 timeframe. The drug is still investigational with no FDA submission filed.

zenagamtide Updated Nov 5

What to watch

Watch for Phase 3 AMAZE trial enrollment updates and any interim analysis announcements from Novo Nordisk, though no topline readouts are expected before 2028. The more immediate pipeline catalyst for NVO is the FDA decision on CagriSema, which has already been filed. Zenagamtide remains a longer-term pipeline story with promising early data but no near-term binary event.

Bull case
  • Phase 2 data showed strong efficacy: up to 14.6% weight loss in type 2 diabetes and up to 24.3% in early obesity studies, competitive with or exceeding existing GLP-1 drugs.
  • The oral formulation could be a key differentiator in the obesity market, offering a pill alternative to injectables like Wegovy and Zepbound.
  • The unimolecular GLP-1/amylin mechanism is novel and could provide differentiated efficacy and tolerability vs Novo's own CagriSema (a combination of two separate molecules).
Bear case
  • Phase 3 trials just started recruiting (Aug-Sep 2026) with estimated completion in 2028, meaning no near-term catalyst and years before potential commercialization.
  • Novo Nordisk's stock has fallen ~46% from its 52-week high of $64.16 to ~$40, reflecting broader pipeline and competitive concerns. Morgan Stanley downgraded NVO to Underweight in September 2026.
  • Intense competition: Eli Lilly's retatrutide (triple agonist) showed ~28.3% weight loss, and Novo's own CagriSema (already filed for FDA approval) may cannibalize zenagamtide's future market.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercially available in the US (FDA approved December 2024, label expanded July 2025) and EU (EMA approved December 2024, expanded July 2025).

Alhemo concizumab Updated Nov 6

What to watch

Alhemo is already approved and launching commercially in both the US and EU. The next meaningful event would be quarterly sales disclosures from Novo Nordisk, but as a small part of a GLP-1-dominated portfolio, Alhemo-specific revenue is unlikely to move NVO shares. Watch for any future pediatric label expansion efforts or new clinical data at hematology congresses.

Bull case
  • Alhemo is the first once-daily subcutaneous prophylaxis approved for hemophilia A and B both with and without inhibitors, offering a convenient alternative to intravenous factor replacement.
  • Phase 3 explorer7 and explorer8 trials demonstrated significant reductions in annualized bleeding rates, and explorer10 data (ISTH July 2026) showed an 82% bleed reduction in children under 12 with inhibitors.
  • The global hemophilia market is estimated at ~$15-17 billion in 2026 and growing at 5-7% CAGR, providing a large addressable market for a novel non-factor therapy.
Bear case
  • Alhemo faces entrenched competition from Roche's Hemlibra (emicizumab), Sanofi's newly approved Qfitlia (fitusiran), and Pfizer's Hympavzi (marstacimab), all targeting similar hemophilia populations.
  • Novo Nordisk withdrew its EMA application to extend Alhemo to children under 12 in September 2026, citing partial data from an ongoing study, capping the addressable pediatric market.
  • As a once-daily subcutaneous injection, Alhemo may face adherence and convenience challenges versus less frequent dosing options like monthly fitusiran.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and launched in the US (August 2026), EU (May 2024), Canada, and Switzerland. Currently in the early commercialization phase.

Awiqli insulin icodec Updated Nov 5

What to watch

Awiqli is already approved and launching, so there are no binary catalysts ahead. The key metrics to watch are quarterly prescription trends, formulary coverage wins versus Lilly's Onswik, and any signal of whether Awiqli can expand into type 1 diabetes. For NVO investors, Awiqli is a minor factor compared to the Wegovy pill rollout and GLP-1 competitive dynamics with Lilly.

Bull case
  • First-mover advantage: Awiqli is the first once-weekly basal insulin approved in the US, giving Novo Nordisk a head start in building brand loyalty and formulary access before Lilly's Onswik gains traction.
  • Convenience-driven adherence: Reducing injections from 365 to 52 per year could improve patient adherence, potentially expanding the treated population and driving market growth for once-weekly basal insulins.
  • Pediatric expansion: The October 2026 FDA approval for children 10+ with type 2 diabetes opens an additional patient segment with no direct once-weekly competitor yet approved for that age group.
Bear case
  • Direct competition from Lilly: Eli Lilly's Onswik (efsitora alfa) was approved by the FDA on September 24, 2026, just six months after Awiqli. Consensus forecasts from S&P Global indicate Lilly's product may ultimately outsell Awiqli.
  • Type 1 diabetes exclusion: Awiqli is not approved for type 1 diabetes, which represents a significant portion of the basal insulin market. Safety concerns (hypoglycemia risk) may prevent expansion into type 1.
  • Pricing and reimbursement pressure: As a branded insulin in a market accustomed to low-cost generics and biosimilars, Awiqli faces pricing headwinds, though the $35 Medicare Part D cap on insulin provides some pricing floor.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed since February 2019 in the US, EU, Canada, Japan, and Switzerland.

Esperoct turoctocog alfa pegol Updated Nov 6

What to watch

Esperoct has no upcoming binary catalyst. The drug is already approved and marketed, and Novo Nordisk's stock is overwhelmingly driven by its GLP-1 obesity/diabetes franchise (Wegovy, Ozempic), not its rare-disease hemophilia portfolio. Investors should watch for any competitive pressure from newer extended half-life factor VIII products or gene therapies, but Esperoct alone will not move NVO shares in any material way.

Bull case
  • Esperoct is an FDA-approved, well-characterized extended half-life factor VIII therapy with a established safety and efficacy profile across adults and children with hemophilia A, providing steady recurring revenue.
  • A completed real-world joint health observational study (NCT05621746) could strengthen Esperoct's clinical profile if results show improved joint protection, supporting continued prescribing.
  • The hemophilia A market is projected to grow at a CAGR of ~9% through 2036, and Esperoct's once-approved status in multiple regions (US, EU, Canada, Japan, Switzerland) gives it a global commercial footprint.
Bear case
  • Esperoct competes in a crowded hemophilia A market with many extended half-life factor VIII products (Eloctate, Adynovate, Jivi, Kovaltry) and emerging gene therapies (Hemgenix, Roctavian) that could erode its market share.
  • As a small part of Novo Nordisk's portfolio, Esperoct receives minimal strategic focus compared to the company's massive GLP-1 obesity/diabetes franchise, limiting investment in commercial expansion.
  • Pricing pressure from payers and biosimilar competition in the biologics space could compress margins on rare-disease products like Esperoct over time.
● neutral
Impact
PhaseApproved / Commercial
Time to marketAlready approved and commercializing in the EU (since Nov 2025), China (since Jul 2026), and Brazil (since Sep 2026). No US filing planned.

Kyinsu insulin icodec / semaglutide Updated Nov 6

What to watch

Kyinsu is already approved in the EU, China, and Brazil with no pending US filing. The next near-term event is the European Commission's formal decision on the CHMP-recommended indication change (positive opinion October 15, 2026), which is a routine label expansion, not a binary catalyst. Watch for commercial uptake data in Novo Nordisk's quarterly earnings and any potential US regulatory path if the insulin icodec issues are resolved.

Bull case
  • First-in-class product: Kyinsu is the world's first once-weekly fixed-ratio combination of basal insulin and a GLP-1 receptor agonist, offering a convenience advantage over daily injections.
  • Positive Phase 3 COMBINE data: The COMBINE 3 trial showed non-inferior HbA1c reduction vs daily basal-bolus insulin with fewer injections (once-weekly vs multiple daily shots).
  • Expanding geographic reach: Approved in EU (Nov 2025), launched in China (Jul 2026), and approved in Brazil (Sep 2026), with a recent CHMP positive opinion for an indication label expansion (Oct 2026).
Bear case
  • No US filing path: Novo Nordisk stated it will not file IcoSema in the US after the FDA rejected insulin icodec (Awiqli) in July 2024 over hypoglycemia concerns, cutting off the world's largest pharma market.
  • Competitive pressure from Eli Lilly's Mounjaro (tirzepatide) and other GLP-1/insulin combos could limit Kyinsu's commercial uptake outside the US.
  • Novo Nordisk is a mega-cap company (~$190B+ market cap) where Kyinsu is one of many products; even strong EU/China sales would have a modest impact on the stock.
● neutral
Impact
PhaseApproved
Time to marketAlready marketed since 2013 (US) and 2014 (EU).

NovoEight turoctocog alfa Updated Nov 6

What to watch

No upcoming binary catalysts exist for NovoEight. Investors should watch for any biosimilar entry following patent expirations, and monitor Novo Nordisk's quarterly rare disease segment sales for trends. The drug's commercial trajectory is a rounding error for NVO's overall thesis, which is dominated by semaglutide (Ozempic/Wegovy) dynamics.

Bull case
  • NovoEight is a well-established, FDA-approved therapy with over a decade of real-world safety and efficacy data across all age groups.
  • Novo Nordisk's rare disease portfolio (including NovoEight, Esperoct, and Alhemo) grew 9% at CER in 2025, showing continued commercial traction.
  • The drug's room-temperature stability (up to 40 degrees C) offers convenience advantages over some competitors that require strict refrigeration.
Bear case
  • NovoEight is a standard half-life factor VIII facing cannibalization from Novo Nordisk's own Esperoct (extended half-life pegylated version), which requires fewer infusions.
  • Patent expirations around 2025 create potential for biosimilar competition, which could erode pricing and market share.
  • The broader hemophilia A market is shifting toward extended half-life products, gene therapies (e.g. Hemgenix, Roctavian), and bispecific antibodies (e.g. Mim8 in development), making standard half-life products like NovoEight increasingly legacy.
● neutral
Impact
PhaseApproved (FDA approvals dating to 2000)
Time to marketAlready approved and commercially available since 2000.

NovoLog insulin aspart Updated Aug 22

What to watch

NovoLog is a mature, off-patent insulin with no binary catalysts ahead, not a stock-moving event for a ~$207B market-cap company. Investors should watch biosimilar erosion (Amphastar's I004) and Novo Nordisk's overall diabetes revenue mix shift toward GLP-1s, not NovoLog specifically. If you own NVO, this drug alone is not a thesis driver.

Bull case
  • NovoLog is an established brand with decades of real-world use, physician familiarity, and formulary access that creates switching inertia even after patent expiry.
  • Novo Nordisk's vertically integrated insulin manufacturing scale provides a cost advantage that makes it hard for biosimilar entrants to undercut significantly.
  • Diabetes prevalence continues to grow globally (~537M adults), providing steady demand tailwinds even if NovoLog's share shrinks.
Bear case
  • Off-patent and facing biosimilar competition: Amphastar's I004 (insulin aspart biosimilar) has completed Phase 3 trials referencing NovoLog, which will likely erode pricing and volume.
  • Insulin pricing has faced persistent political/market pressure in the U.S., including Medicare Part D redesign and state price-gouging laws compressing margins.
  • Novo Nordisk's pipeline and commercial focus has shifted sharply toward GLP-1 drugs (Ozempic, Wegovy), which now drive growth, NovoLog is a legacy product with declining strategic importance.
● neutral
Impact
PhaseApproved
Time to marketAlready on the market since 1999 (original) and 2014 (RT formulation).

NovoSeven eptacog alfa (activated) Updated Nov 5

What to watch

NovoSeven has no near-term binary catalyst. The Phase 4 postpartum hemorrhage safety study in India (NCT07157423) is still recruiting with no announced readout date. For Novo Nordisk investors, the drug is a mature, low-growth asset within a tiny segment of the business. The key drivers for NVO remain the GLP-1 franchise (Ozempic, Wegovy) and pipeline assets like oral semaglutide and CagriSema, not NovoSeven.

Bull case
  • NovoSeven is a well-established, FDA-approved therapy with multiple labeled indications (hemophilia A/B with inhibitors, congenital FVII deficiency, Glanzmann's thrombasthenia, acquired hemophilia), giving it a broad addressable patient population.
  • The rare disease portfolio grew 9% at constant exchange rates in 2025, per Novo Nordisk's annual report, showing steady demand for products like NovoSeven.
  • A Phase 4 study exploring safety in severe postpartum hemorrhage in India could support future label expansion or guideline inclusion, opening a new use case.
Bear case
  • NovoSeven faces direct competition from SevenFact (eptacog beta, LFB), a newer recombinant Factor VIIa approved for hemophilia A/B with inhibitors in patients aged 12 and older, which has been winning formulary conversions at some institutions.
  • Patent protection is eroding; biosimilar versions such as AryoSeven (AryoGen, Iran) already exist outside the US, and the broader biosimilar patent cliff could eventually bring US competition.
  • NovoSeven is a negligible financial contributor to Novo Nordisk. The company's 2025 revenue was DKK 309 billion (~$49B), with the rare disease segment accounting for only about 6% of sales. The stock's performance is overwhelmingly driven by GLP-1 products (Ozempic, Wegovy), not NovoSeven.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed since 2012-2013 in major regions.

NovoThirteen catridecacog Updated Nov 6

What to watch

No near-term binary catalysts exist for NovoThirteen. The drug is already approved and marketed in major regions (US, EU, Japan, Australia, Canada) for an ultra-rare indication. Watch for any potential label expansion or new competition in the factor XIII space, but neither appears imminent. This drug has no material impact on NVO's investment thesis.

Bull case
  • NovoThirteen is the only recombinant factor XIII A-subunit therapy approved for congenital FXIII deficiency, giving it a monopoly position in an ultra-rare indication with no direct recombinant competitor.
  • The drug has orphan drug designation in both the US and EU, providing market exclusivity protections and regulatory advantages.
  • As a chronic prophylaxis treatment (monthly IV infusion), it generates recurring revenue from a stable, small patient population.
Bear case
  • The addressable patient population is extremely small (congenital FXIII deficiency affects roughly 1 in 2 million people globally), capping peak revenue potential at a very low level.
  • NovoThirteen is a negligible contributor to Novo Nordisk's overall revenue, which exceeded $47 billion in 2025. Even a complete loss of the product would be immaterial to the stock.
  • No upcoming catalysts or label expansion opportunities were identified that could meaningfully change the drug's commercial trajectory.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed in the US (since 2017) and EU (since 2017).

Refixia nonacog beta pegol Updated Nov 6

What to watch

Refixia/Rebinyn is a mature, approved product with no upcoming binary catalysts. Watch for quarterly Novo Nordisk rare disease segment revenue trends and any competitive developments from CSL's Hemgenix gene therapy or newer non-factor therapies like Mim8 (denecimig) that could shift the hemophilia B treatment landscape.

Bull case
  • Extended half-life (glycoPEGylated) allows once-weekly prophylactic dosing versus 2-3 times weekly for standard FIX products, improving patient convenience.
  • Approved for both on-demand treatment and routine prophylaxis in adults and children across the US (as Rebinyn) and EU (as Refixia), covering the full hemophilia B treatment spectrum.
  • Long-term safety and efficacy data from the Paradigm clinical program, including 5-year pediatric data, support a well-established profile.
Bear case
  • Faces direct competition from other extended half-life FIX products including Alprolix (Sanofi) and Idelvion (CSL Behring), as well as standard half-life products like BeneFIX.
  • Gene therapy Hemgenix (CSL Behring) offers a one-time curative option that could shrink the addressable patient pool for chronic factor replacement over time.
  • Newer non-factor therapies such as Hympavzi (marstacimab) and Novo Nordisk's own investigational Mim8 (denecimig) could disrupt the factor replacement market.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed in the US (since 2020) and EU (since 2021). The EU label expansion for three pediatric indications is pending European Commission decision, expected before year-end 2026.

Sogroya somapacitan-beco Updated Nov 5

What to watch

The next catalyst is the European Commission's decision on Sogroya's three new pediatric indications (ISS, SGA, Noonan syndrome), expected before year-end 2026. The CHMP has already issued a positive opinion after re-examination, so approval is widely expected. Given Sogroya's small contribution to Novo Nordisk's total revenue (combined Norditropin/Sogroya sales were ~DKK 6B in 2025 vs. total revenue of ~DKK 309B), even a positive decision is unlikely to move NVO shares materially.

Bull case
  • Sogroya is the first and only once-weekly long-acting growth hormone approved for both adult and pediatric patients, offering a convenience advantage over daily injections like Norditropin.
  • The FDA approved three new pediatric indications in February 2026 (ISS, SGA, Noonan syndrome), expanding the addressable patient population significantly.
  • The EU CHMP has recommended Sogroya for the same three pediatric indications after re-examination; if the European Commission approves, it would be the first growth hormone authorized for ISS in the EU.
Bear case
  • Sogroya is a tiny fraction of Novo Nordisk's revenue (combined Norditropin/Sogroya sales ~DKK 6B in 2025 vs. total ~DKK 309B), so even major label expansions have negligible impact on NVO's stock.
  • The growth hormone market faces long-term biosimilar erosion risk; Sogroya's US biologic exclusivity runs from 2020 into 2032, but patent challenges could emerge.
  • EMA flagged lipoatrophy and lipohypertrophy safety signals in children, requiring a type II variation to update the EU label.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed since 2015.

Tresiba insulin degludec Updated Nov 5

What to watch

Watch for biosimilar development activity as Tresiba's reference exclusivity approaches expiration around September 2027. Any FDA filing or clinical data from biosimilar developers (e.g., Chinese manufacturers with active programs) could signal future revenue erosion. For Novo Nordisk investors, Tresiba's commercial trajectory is a secondary concern behind the GLP-1 competitive dynamics with Eli Lilly's Mounjaro/Zepbound.

Bull case
  • Tresiba's ultra-long duration (>42 hours) and flexible once-daily dosing (at least 8 hours between doses) are unique among basal insulins, supporting continued prescribing preference.
  • The DEVOTE cardiovascular outcomes trial showed a 53% reduction in severe nocturnal hypoglycemia versus insulin glargine, a clinically meaningful differentiator.
  • No FDA-approved biosimilar for insulin degludec exists as of late 2026, giving Tresiba continued market exclusivity until at least late 2027 (reference exclusivity) or later (patent-protected into 2031).
Bear case
  • Tresiba faces intense competition from well-established basal insulins including Lantus (insulin glargine), its interchangeable biosimilars Semglee and Rezvoglar, and Sanofi's Toujeo, all of which exert pricing pressure.
  • The 72% US list-price cut (effective January 2026) directly reduces per-unit revenue, and Novo Nordisk discontinued unbranded biologic versions of Tresiba, signaling margin compression.
  • Reference biologic exclusivity is estimated to expire around September 2027, and biosimilar developers (including Chinese manufacturers) have active programs, posing a medium-term erosion risk.
▼ bearish
Impact
PhaseApproved
Time to marketAlready approved and marketed since 2010.

Victoza liraglutide Updated Oct 27

What to watch

Victoza is a tail-end asset with no upcoming binary catalyst. For Novo Nordisk investors, watch GLP-1 class dynamics, generic liraglutide erosion is already priced in, but the FDA's shortage status (still active as of Oct 2026) could create short-term supply-driven revenue variability. The real stock drivers are semaglutide (Ozempic/Wegovy) competitive positioning and the oral Wegovy rollout, not this legacy product.

Bull case
  • Established safety record: liraglutide has over 16 years of real-world use and remains the only GLP-1 with a dedicated cardiovascular outcomes trial (LEADER) proving risk reduction in type 2 diabetes patients with established CVD.
  • FDA shortage status still active as of Oct 2026 means some patients who cannot find generic alternatives may still rely on branded Victoza, providing a modest revenue floor.
  • Broad label: Victoza is approved for adults, pediatric patients 10+, and carries a CV risk-reduction indication, differentiating it from some newer entrants that lack pediatric data.
Bear case
  • Generic erosion accelerating: Teva launched an authorized generic in June 2024 and Hikma received FDA approval for a full ANDA generic in December 2024, driving Victoza revenue down ~45% YoY to DKK 3.0B in FY2025.
  • Novo Nordisk has largely moved on, the company's pipeline and commercial focus have shifted to semaglutide (Ozempic, Wegovy, Rybelsus) and next-generation obesity drugs, making Victoza a legacy product with declining investment.
  • Superior alternatives exist: semaglutide and tirzepatide offer better efficacy (e.g. 6.4% weight loss for liraglutide vs 15.8% for semaglutide head-to-head), so Victoza faces both branded and generic competitive pressure.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed (FDA approval November 21, 2016).

Xultophy insulin degludec and liraglutide Updated Nov 5

What to watch

Xultophy is an approved, marketed drug with no upcoming binary catalyst. The key event to watch is the projected loss of exclusivity around November 2028, which could open the door to biosimilar competition. For Novo Nordisk investors, Xultophy is a minor product within a portfolio dominated by semaglutide (Ozempic, Wegovy, Rybelsus); any material news would likely come from the broader GLP-1 competitive landscape or patent challenges rather than Xultophy-specific developments.

Bull case
  • Xultophy is an FDA-approved, commercially established product with a decade of real-world use and safety data, providing a steady revenue stream for Novo Nordisk.
  • The fixed-ratio combination of basal insulin (degludec) and GLP-1 (liraglutide) offers a convenient once-daily injection for type 2 diabetes patients who need both therapies, addressing a clear clinical need.
  • Liraglutide has demonstrated cardiovascular and renal protective benefits in high-risk type 2 diabetes patients, which may support continued prescribing preference.
Bear case
  • Xultophy faces direct competition from Sanofi's Soliqua (insulin glargine/lixisenatide), which was approved by the FDA on the same day in November 2016 and targets the same patient population.
  • Projected loss of exclusivity around November 2028 (12-year biologic exclusivity estimate) opens the door to biosimilar competition, which could erode market share and pricing power.
  • Novo Nordisk's overall 2026 outlook includes a forecasted sales decline of 5-13% at constant exchange rates, reflecting pricing pressure and competition from Eli Lilly in the broader GLP-1 market.
● neutral
Impact
PhasePhase 1/2
Time to marketLikely 5+ years away from potential approval, given the drug is in Phase 1/2 with no pivotal trials initiated or even designed yet.

amylin 355 nnc0638-0355 Updated Nov 6

What to watch

No near-term binary catalyst is scheduled for Amylin 355. The next meaningful event would be topline data from the Phase 1/2 EU trial (2026-526797-16-00), which is still recruiting 380 participants with a 26-week treatment period, so readout is likely 12-18+ months away. For NVO investors, this is a pipeline-watch item, not a near-term trading driver; the stock's direction will be set by CagriSema's FDA decision (expected around October 2026 per some sources), Wegovy/Zepbound competition, and broader obesity-market dynamics.

Bull case
  • Amylin 355 targets the amylin receptor pathway, a distinct biological mechanism from GLP-1 that regulates satiety and energy metabolism, offering a potential complementary or alternative approach to existing obesity drugs like Wegovy.
  • Novo Nordisk is developing both injectable and oral (tablet) formulations of NNC0638-0355, expanding the potential delivery options and patient reach.
  • The global obesity drug market is projected to grow to tens of billions of dollars, and a differentiated once-weekly amylin analogue could capture meaningful share if it demonstrates a competitive efficacy/tolerability profile.
Bear case
  • Amylin 355 is very early-stage (Phase 1/2) with no published efficacy data; it is years away from any regulatory filing and could fail to show meaningful weight loss or acceptable tolerability in larger trials.
  • Novo Nordisk already has a more advanced amylin asset, cagrilintide (Phase 3 as monotherapy and in CagriSema), which underperformed Wegovy on weight loss in Phase 3, raising questions about the amylin class's standalone potential.
  • Eli Lilly is aggressively developing its own amylin assets and recently reported 20%+ weight loss with an amylin combination, intensifying competitive pressure in the obesity space.
● neutral
Impact
PhaseApproved
Time to marketAlready approved (2015) but discontinued in the US. Still available in some international markets.

Ryzodeg insulin degludec and insulin aspart Updated Nov 5

What to watch

Ryzodeg is a legacy product with no upcoming catalysts and has been discontinued in the US. For Novo Nordisk (NVO) investors, the drug is not a factor in the investment thesis. Watch NVO's Q3 2026 earnings and the ongoing competitive dynamics between Novo Nordisk's GLP-1 franchise (Ozempic, Wegovy) and Eli Lilly's incretin portfolio instead.

Bull case
  • Ryzodeg remains approved and available in several international markets (e.g., New Zealand, UAE, Australia until recently), providing ongoing revenue in those regions.
  • The drug offers a convenient once-daily pre-mixed insulin option that combines basal and prandial coverage, which may retain niche demand where still marketed.
  • Novo Nordisk's dominant position in diabetes care means the company can shift patients to alternative insulin products in its portfolio.
Bear case
  • Ryzodeg has been discontinued in the US market, its largest potential market, and is no longer available to new or existing patients there.
  • The product faces intense competition from other pre-mixed insulins (NovoLog Mix 70/30, Humalog Mix 75/25) and from the broader shift toward GLP-1 receptor agonists (Ozempic, Mounjaro) for diabetes management.
  • Discontinuation in Australia (February 2025) and other markets suggests a broader commercial wind-down of the product globally.

Other drugs in filings and trials

no drug report yet
  • AWIQLI FLEXTOUCH Last: Approval · Mar 26, 2026
  • RIVFLOZA Last: Approval · Sep 29, 2023
  • RYBELSUS Last: Approval · Jan 16, 2020
  • OZEMPIC Last: Approval · Sep 20, 2019
  • FIASP PENFILL Last: Approval · Sep 29, 2017
  • SAXENDA Last: Approval · Dec 23, 2014
  • nedosiran 1 trial
  • NNC0662-0419 1 trial
  • NNC6019-0001 1 trial
  • Semaglutide and Behavioral Program 1 trial
  • Ziltivekimab 2 trials

Past FDA events & how the stock moved

14 events
DateDrugEvent1 day5 days
Mar 26, 2026AWIQLI FLEXTOUCHApproval−0.8%+5.5%
Dec 22, 2025WegovyApproval+7.3%+6.5%
Jul 31, 2025AlhemoApproval−3.7%−2.5%
Dec 20, 2024AlhemoApproval−14.2%−17.1%
Sep 29, 2023RIVFLOZAApproval+0.3%+0.7%
Jun 4, 2021WegovyApproval+1.9%+6.0%
Aug 28, 2020SogroyaApproval−0.3%−1.7%
Jan 16, 2020RYBELSUSApproval−1.7%−2.1%
Sep 20, 2019OZEMPICApproval+2.1%−0.5%
Dec 5, 2017OZEMPICApproval+2.0%+4.5%
Sep 29, 2017FIASP PENFILLApproval+1.8%+2.2%
Nov 21, 2016XultophyApproval−2.0%+0.9%
Sep 25, 2015RyzodegApproval−0.8%−0.1%
Dec 23, 2014SAXENDAApproval−0.7%−4.1%

Clinical trials

39 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
ZiltivekimabARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart AttackPhase 3Active not recruiting10,000Jan 29, 2027
AwiqliA Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 DiabetesPhase 3Active not recruiting877Jan 25, 2027
NNC0662-0419A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or ObesityPhase 2Active not recruiting224Dec 14, 2026
ZiltivekimabA Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and InflammationPhase 3Terminated4,874Sep 3, 2026
WegovyA Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level in Japanese People With Type 2 DiabetesPhase 3Completed267Jun 29, 2026
Semaglutide and Behavioral ProgramLifestyle Counseling and Medication for Adolescent Weight ManagementPhase 2Completed · results121Jun 29, 2026
CagriSemaA Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral NeuropathyPhase 2Completed142Jun 26, 2026
Ziltivekimab BZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and InflammationPhase 3Completed6,385Jun 9, 2026
WegovyA Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or BothPhase 3Completed1,023Jun 2, 2026
WegovyEffects of Dapagliflozin, Semaglutide, and Their Combination in Heart Failure Patients With Prosthetic Heart ValvesPhase 2Completed160Apr 29, 2026
WegovyA Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose WeightPhase 3Completed300Apr 22, 2026
etavopivatStudy of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell DiseasePhase 2Completed12Mar 9, 2026
WegovyA Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese SubjectsPhase 3Completed408Mar 7, 2026
WegovyA Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 InhibitorPhase 3Completed1,024Mar 4, 2026
WegovyA Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose WeightPhase 3Completed809Dec 8, 2025
VictozaEffect of Liraglutide in Obese Women With Polycystic Ovary SyndromePhase 3Completed183Nov 30, 2025
WegovyEffects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver DiseasePhase 2Completed270Nov 21, 2025
WegovyA Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 InhibitorPhase 3Completed2,734Nov 19, 2025
WegovyA Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and ExercisePhase 3Completed189Oct 1, 2025
NNC0487-0111 subcutanousA Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 DiabetesPhase 2Completed448Oct 1, 2025
WegovyA Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and PlaceboPhase 2Completed626Sep 24, 2025
NNC0519-0130A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 DiabetesPhase 2Completed299Sep 19, 2025
WegovyA Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)Phase 3Completed1,840Sep 16, 2025
WegovyA Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)Phase 3Completed1,840Sep 15, 2025
WegovyA Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without MetforminPhase 3Completed274Sep 9, 2025
insulin glargineEffect of Topical Insulin on Healing Rate of Pemphigus LesionsPhase 2Completed20Aug 10, 2025
NDec - oral decitabine-tetrahydrouridineResearch Study Investigating How Well NDec Works in People With Sickle Cell DiseasePhase 2Completed96Jul 24, 2025
KyinsuA Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)Phase 3Completed485May 27, 2025
AwiqliA Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 DiabetesPhase 3Completed · results412May 8, 2025
WegovyA Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 DiabetesPhase 3Completed · results132Apr 29, 2025
WegovyA Study Comparing the Effects of BGM0504 Injection and Semaglutide Injection on Obese Subjects.Phase 2Completed60Apr 25, 2025
AwiqliA Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 DiabetesPhase 3Completed · results148Apr 14, 2025
NNC0519-0130A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose WeightPhase 2Completed354Apr 10, 2025
WegovySemaglutide 2.4 mg in Patients With Poor Weight-lossPhase 3Completed · results70Apr 9, 2025
WegovyA Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight RangePhase 3Completed · results242Apr 2, 2025
WegovyA Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)Phase 3Completed · results573Mar 5, 2025
NNC6019-0001A Research Study to Look at How a New Medicine Called NNC6019-0001 Works and How Safe it is for People Who Have Heart Disease Due to Transthyretin (TTR) AmyloidosisPhase 2Completed105Feb 17, 2025
nedosiranNedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal FunctionPhase 2Completed · results27Feb 5, 2025
WegovyA Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP)Phase 3Completed · results1,407Oct 30, 2024

1 newer trial for subscribers. See plans